Panel Discussion | Exploring Next Generation RNA-Based Therapeutics to Access Undruggable CNS Targets with High Specificity & Target Engagement
1:30 pm - Wednesday 9th December 2026
- Exploring the latest RNA editing approaches to target APOE, such as Rznomics’ trans-splicing-induced replacement of APOE4
- Discussing the potential of RNAi platforms to transverse the BBB and silence disease-causing genes in the brain
- Evaluating opportunities for ASOs, such as Sovargen’s SVG105, to achieve greater efficacy than conventional gene and small molecule therapies in epilepsies
- Evaluating novel exosome-based and lipid carrier platforms for CNS-targeted RNA therapeutics
